Trends in Immunotherapy

Article

Initiatives for immune-related adverse events by the outpatient pharmacist clinic

Downloads

https://doi.org/10.24294/ti.v6.i1.1385
Hamatake, K., & Kojima, K. (2022). Initiatives for immune-related adverse events by the outpatient pharmacist clinic. Trends in Immunotherapy, 6(1). https://doi.org/10.24294/ti.v6.i1.1385
Volume 6 Issue 1 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Kiyonori Hamatake
    Department of Pharmacy, Takatsuki Red Cross Hospital
  • Kazuaki Kojima Department of Pharmacy, Takatsuki Red Cross Hospital

Early detection is the key in managing side effects because immune-related adverse events (irAEs) are becoming more serious, and their onset time differs. In our hospital, we conducted an outpatient pharmacist clinic for early detection of irAEs by self-care practice for the cases of immune checkpoint inhibitor administration. As a result of a retrospective survey of 207 cases, the percentage of irAEs found by pharmacist’s suggestion of the outpatient pharmacist clinic increased over time, and a high detection ratio was obtained even for irAEs with a late onset time. The incidence of serious irAEs was higher than that in the immediate post-marketing surveillance, and different factors were considered. Although there were some problems, the outpatient pharmacist clinic had a certain effect.

Keywords:

Immune Checkpoint Inhibitors Immune Combination Therapies Immune-related Adverse Events Outpatient Pharmacist Clinic Clinical Pathway

References

  1. Furukawa F. The Nobel prize in physiology or medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends in Immunotherapy 2018; 2. doi: 10.24294/ti.v2.i3.1065
  2. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. The Lancet Oncology 2021; 22(2): 198–211. doi: 10.1016/S1470-2045(20)30641-0
  3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019; 381(16): 1535–1546. doi: 10.1056/NEJMoa1910836
  4. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine 2018; 378(14): 1277–1290. doi: 10.1056/NEJMoa1712126
  5. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends in Immunotherapy 2017; 1(1): 2–9. doi: 10.24294/ti.v1.i1.20
  6. Noguchi T, Nakagawa M, Takagi J, et al. Effectiveness of reverse manual for immune-related adverse events (in Japanese). Japanese Journal of Lung Cancer 2021; 61(1): 17–23. doi: 10.2482/haigan.61.17
  7. Yoshino K. The management of immune-related adverse events associated with immune checkpoint inhibitors (in Japanese). Skin Allergy Frontier 2018; 16(1): 29–33.
  8. Watanabe H, Hata K, Ikeda M, et al. Management of immune-related adverse events based on a multidisciplinary team activity at Kyushu University Hospital (in Japanese). Japanese Journal of Cancer Clinics 2018; 64(5): 307–314.
  9. Shiokawa H, Tsuda T, Nakajima T. Immune checkpoint inhibitor side effect countermeasure team practice (in Japanese). The Pharmaceuticals Monthly 2017; 59(12): 2449–2454.